Background: Alcohol consumption is an established risk factor for incident breast cancer. However, its role in breast cancer prognosis remains unclear.

Methods: We conducted an investigation of postdiagnosis alcohol consumption with recurrence and mortality among 9,329 breast cancer patients in the After Breast Cancer Pooling Project. Women were diagnosed from 1990 to 2006 with AJCC Stage I-III breast tumors from three prospective US cohorts. Alcohol intake was assessed at cohort entry (mean 2.1 years postdiagnosis) using a food frequency questionnaire. HR and 95% confidence intervals (CI) were estimated using delayed entry Cox proportional hazards models with adjustment for known prognostic factors.

Results: After a mean follow-up of 10.3 years, 1,646 recurrences and 1,543 deaths were ascertained. 5,422 women (58%) were considered drinkers (≥0.36 g/day of alcohol, ≥0.25 drinks/week) with a median of 5.3 g/day. Overall, compared with nondrinking, regular alcohol intake (≥6.0 g/day) was not associated with risk of recurrence (HR for 6 to less than 12 g/day, 1.03; 95% CI, 0.86–1.24; HR for 12 to less than 24 g/day, 1.12; 95% CI, 0.93–1.34; HR for ≥24 g/day, 1.04; 95% CI, 0.84–1.31). However, risk varied significantly by menopausal status (P for interaction < 0.05). Postmenopausal women who regularly consumed alcohol (≥6.0 g/day) had increased risk of recurrence (HR, 1.19; 95% CI, 1.01–1.40). Alcohol intake was not associated with mortality.

Conclusions: Regular alcohol consumption was not associated with breast cancer recurrence and total mortality overall, yet recurrence risk was only elevated in postmenopausal women.

Impact: The association between alcohol intake and recurrence may depend on menopausal status at breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev; 22(1); 32–41. ©2012 AACR.

This article is featured in Highlights of This Issue, p. 1

In 2011, the estimated number of breast cancer survivors in the US was over 2.6 million, and the population continues to grow (1, 2). Many women living with breast cancer are keenly interested in how they can improve their prognosis and survival by making lifestyle changes after their diagnosis. One factor of particular interest is alcohol consumption, which is generally recognized to increase the risk of breast cancer (3–5). However, inconclusive results have emerged from the limited number of studies that have examined alcohol intake (primarily before diagnosis) and breast cancer-related outcomes.

Previous studies have reported increased (6–9) and decreased risks of death (10–13) with pre- and postdiagnosis alcohol consumption, as well as no association (14–24). Fewer studies have examined the association of alcohol on breast cancer recurrence, with mixed results (6, 13, 25, 26).

Overall, studies of alcohol and breast cancer prognosis have suffered from methodologic challenges, namely, varied endpoints, narrow exposure (drinking) range, prediagnosis rather than postdiagnosis assessment of intake, and failure to adjust for prognostic factors (27, 28). Alcohol might influence breast cancer risk and prognosis by increasing estrogen metabolism and endogenous estrogen levels, particularly in postmenopausal women (29–33). However, epidemiologic studies to date have not had adequate sample size to conduct subgroup analyses by estrogenic factors.

To address these limitations, we conducted one of the largest pooled investigations of postdiagnosis alcohol consumption and breast cancer recurrence and total mortality using data from 9,329 US breast cancer survivors in the After Breast Cancer Pooling Project (ABCPP). We also examined potential effect modification by a priori selected estrogenic factors including menopausal status, tumor estrogen receptor (ER) status, and obesity.

The After Breast Cancer Pooling Project

The ABCPP is an international collaboration of pooled data from 4 prospective studies of breast cancer survivors to examine the roles of physical activity, adiposity, dietary factors, supplement use, and quality of life in breast cancer prognosis. Details about cohort creation and characteristics have been published previously (34). Briefly, the ABCPP includes 18,333 breast cancer survivors diagnosed with stage I-IV invasive breast cancer from 4 population-based prospective cohort studies recruited from the US and Shanghai, China: the Shanghai Breast Cancer Survival Study (SBCSS; ref. 35), the Life after Cancer Epidemiology (LACE) Study (36), the Women's Healthy Eating and Living (WHEL) Study (37), and breast cancer patients from the Nurses' Health Study (NHS; ref. 38). Each cohort collected data on clinical and reproductive factors, family history of breast cancer, quality of life, medical history, anthropometry, smoking history, alcohol intake, supplement use, physical activity, and diet. In the ABCPP, these data have been harmonized into a common dataset. Individual studies received Institutional Review Board approval from their respective institution(s) to participate in this collaboration.

Alcohol intake

Data from WHEL, LACE, and NHS were included in this analysis, as almost no women in the SBCSS reported alcohol consumption. Postdiagnosis alcohol intake was collected from participants at baseline (entry into cohort for LACE and WHEL) or regular follow-up after diagnosis (NHS) using validated food frequency questionnaires (FFQ).

Alcohol was assessed at baseline (on average 2 years postdiagnosis) in WHEL using the Arizona Food Frequency Questionnaire (39, 40) and in LACE using the Fred Hutchinson Cancer Research Center Food Frequency Questionnaire (FHRCC-FQ; ref. 41). For wine, beer, and liquor, women reported their average frequency of consumption over the past 12 months, and a medium serving size was defined as 1 6-oz glass, 1 12-oz can or bottle, and 1 1.5-oz shot, respectively. For WHEL, other minor sources of alcohol (e.g., vanilla extract and bread) were included in calculations of alcohol intake. The NHS assessed dietary habits using a validated semi-quantitative FFQ approximately every 4 years since diagnosis (38). For wine, beer, and liquor, women reported their average frequency of consumption over the past 12 months, and single serving sizes were defined as 1 4-oz glass, 1 12-oz can or bottle, and 1 standard shot, respectively.

Servings per day in oz was converted to grams (g) per day of alcohol [one standard drink in the United States is commonly 12.0 to 14.0 g of pure alcohol depending on the alcohol by volume of the drink (42)] and categorized as none (<0.36 g/day, considered nondrinkers), 0.36 to less than 6.0 g/day (occasional drinkers), and 6.0 g/day or more (regular drinkers). Half a drink per day (6.0 g) was selected as the cutoff point, given that the median level of intake among drinkers in the combined cohorts was 5.3 g/day and the current guidelines for cancer prevention is 1 drink per day for women with no cancer history (3, 43). Higher categories of consumption were also created to examine dose response relationships among regular drinkers (6.0 to less than 12.0 g/day, 12.0 to less than 24.0 g/day, and ≥24.0 g/day).

Covariates

Sociodemographic and lifestyle factors.

Data included race/ethnicity (non-Hispanic white, non-Hispanic black, Asian, Hispanic, and other), education (less than high school, high school, some college, and college graduate), smoking history at diagnosis (never, past, and current), and menopausal status at diagnosis (premenopausal, postmenopausal, and unknown). Postdiagnosis recreational physical activity in metabolic equivalents (MET-hours/week) was determined on average 2.4 years postdiagnosis (range: 1.4–4.0 years) from semiquantitative questionnaires and classified as meeting or not meeting the 2008 Physical Activity Guidelines of 10 MET-hours/week or more (44). Prediagnosis body mass index (BMI) was calculated from self-reported prediagnosis weight and height at baseline (entry into cohort for WHEL and LACE) or regular follow-up before diagnosis (NHS). The BMI measures from all 3 studies were between 1 and 2 years before breast cancer diagnosis (45).

Clinical characteristics.

Data included age at diagnosis (years), AJCC stage (I, II, III, and IV), ER/progesterone receptor (PR) status (ER+/PR+, ER+/PR−, ER−/PR+, ER−/PR−), surgery (none, lumpectomy, and mastectomy), chemotherapy (no and yes), radiation therapy (no and yes), and hormonal therapy (no and yes). Any comorbidity history consisted of reporting at least one of the following conditions: diabetes, hypertension, myocardial infarction, and/or stroke.

Ascertainment of outcomes

All studies ascertained outcome events by self-report and regular linkage to electronic medical records and vital statistics registries. Reported events were verified by medical record review except self-reported recurrences in the NHS. Cause of death, including breast cancer and cardiovascular disease (CVD), was determined from death certificates and supplemented with medical records if necessary. Details of outcome ascertainment have been published (34).

Primary analytic outcomes were a new breast cancer event, defined as a first recurrence/metastasis or new primary breast cancer (hereafter referred to as recurrence), all-cause mortality, breast cancer mortality, and CVD mortality. New primary breast cancers were longitudinally recorded in all cohorts except the NHS. For NHS participants who did not report a recurrence but died from breast cancer (7.2%), the recurrence date was set 2 years before the date of death (46).

Final analytic sample size

Women were excluded from the analysis if they were diagnosed before 1990 to ensure comparable diagnosis dates and treatment information across the cohorts (n = 2,965 NHS cases), had stage IV breast cancer (n = 126), or had no postdiagnosis alcohol data (n = 1,021) or follow-up time (n = 6). A total of 9,329 breast cancer survivors comprised the final cohort. For the analyses depending on the outcome of interest, we further excluded women with missing outcome data (n = 119 with no recurrence information; n = 19 with no cause of death information), missing covariate data (n = 4), and/or date of recurrence was before start of study follow-up (n = 55). A total of 9,151 observations were available for the recurrence analyses, 9,325 observations for the total mortality analyses, and 9,306 observations for the breast cancer and CVD mortality analyses.

Statistical analysis

Sociodemographic, lifestyle, and clinical characteristics of the pooled cohort and by category of postdiagnosis alcohol intake were summarized by frequency distributions for categorical variables and means with SD for continuous variables.

The multivariable analysis involved 3 steps. First, delayed entry Cox proportional hazards regression models were used to estimate study-specific adjusted HRs and 95% confidence intervals (CI) with time since diagnosis as the time scale (47). The entry date was the date of the first survey after breast cancer diagnosis. For models with breast cancer recurrence as the outcome, the exit date was date of recurrence or date of death (whichever was first), or date of last contact (i.e., date of last follow-up survey or date of last registry linkage, whichever occurred first) for women without an event. For models with mortality as the outcome, the exit date was the date of death or date of last contact. Second, a meta-analysis was conducted with study-specific HRs using inverse-variance weights in random-effects models (48). The Q test statistic was used to assess heterogeneity in risk estimates across studies (49). Evidence for heterogeneity was not observed (P > 0.05); hence, pooled analyses were conducted and presented herein for the alcohol-outcome associations of interest using delayed entry Cox proportional hazards regression models stratified by study (50). The proportional hazards assumption for all Cox models was assessed by Kolmogorov-type supremum tests. Tests for linear trend were conducted by modeling categorical variables on an ordinal scale. Statistical significance was considered as P < 0.05 or 95% CI not overlapping with 1.0.

Covariates for the final Cox models were chosen based on a priori determination from literature review or if a covariate produced a 10% change in the main effect estimate when the covariate was added individually to the Cox model (51). Age at diagnosis, AJCC stage, race/ethnicity, education, menopausal status at diagnosis, hormone receptor status, surgery, treatment, smoking, physical activity, prediagnosis BMI, and comorbidity were retained. All missing values for each covariate were included as dummy variables. To test for the impact of missing covariate information, we ran a complete case analysis, and results were similar to treating missing data as an indicator category. We also conducted a subgroup analysis excluding women who had an early recurrence within the first 2 years of their breast cancer diagnosis (n = 152) to rule out potential effects of reverse causality attributable to underlying disease.

Possible a priori effect modification was evaluated in the associations of alcohol consumption with recurrence and mortality by menopausal status (premenopausal vs. postmenopausal), ER status (ER+ vs. ER−), and obesity (obese vs. nonobese) in stratified analyses. Statistical significance of multiplicative interaction terms was assessed by a Wald test of the cross-product terms between the main exposure (3-level alcohol variable) and the potential effect modifier (dichotomous variable as described above) in the Cox models.

Over a mean follow-up of 10.3 years in the entire cohort, a total of 1,646 recurrences and 1,543 deaths (156 related to CVD) were confirmed. Mean times (range) from index diagnosis to recurrence and death were 5.6 (0.1–16.6) years and 7.8 (1.0, 18.6) years among the women who had the events, respectively. Alcohol consumption was assessed on average 2.1 years postdiagnosis (range: 0.1–14.2 years).

Characteristics of the pooled cohort by nondrinkers, occasional drinkers, and regular drinkers (g/day of alcohol consumption) are given in Table 1. The mean age at breast cancer diagnosis was 58.8 years, and 70.9% were postmenopausal at diagnosis. The majority was non-Hispanic white (88.6%) and had at least some college education (89.7%). Most women (88.4%) were diagnosed with stage I or II tumors, and 83.1% of the tumors were ER+ and/or PR+. Compared with nondrinkers (41.9%), drinkers were more likely to be younger and premenopausal, more educated, diagnosed with earlier stage, hormone receptor positive breast cancer, and received radiation therapy or hormonal therapy. Drinkers also tended to be current or past smokers, more physically active, leaner, and with fewer comorbidities.

Table 1.

Characteristics of the After Breast Cancer Pooling Project (ABCPP) by postdiagnosis alcohol consumption

Overall n = 9,329Nondrinker (<0.36 g/day) n = 3,907Occasional (0.36 to less than 6 g/day) n = 2,880Regular (≥6 g/day) n = 2,542
Age at diagnosis (mean, SD) 58.8 (10.5) 59.8 (10.8) 57.4 (10.0) 58.7 (10.3) 
Prediagnosis BMI (mean, SD) 26.5 (5.4) 27.6 (6.0) 26.2 (5.1) 25.0 (4.3) 
 n (%) n (%) n (%) n (%) 
Race/ethnicity 
 Non-Hispanic white 8,261 (88.6) 3,302 (84.5) 2,578 (89.5) 2,381 (93.7) 
 Non-Hispanic black 248 (2.7) 149 (3.8) 65 (2.3) 34 (1.4) 
 Asian 238 (2.5) 156 (4.0) 66 (2.3) 16 (0.6) 
 Hispanic 308 (3.3) 153 (3.9) 102 (3.5) 53 (2.1) 
 Other 272 (2.9) 146 (3.8) 69 (2.4) 57 (2.2) 
Education 
 Less than high school 113 (1.2) 65 (1.7) 29 (1.0) 19 (0.7) 
 High school 846 (9.1) 416 (10.7) 242 (8.4) 188 (7.4) 
 Some college 1,652 (17.7) 740 (18.9) 496 (17.2) 416 (16.4) 
 College grad or higher 6,714 (72.0) 2,685 (68.7) 2,113 (73.4) 1,916 (75.5) 
Menopausal status at diagnosis 
 Premenopausal 2,222 (23.8) 843 (21.6) 754 (26.2) 625 (24.6) 
 Postmenopausal 6,613 (70.9) 2,836 (72.6) 1,983 (68.8) 1,794 (70.6) 
 Unknown 494 (5.3) 228 (5.8) 143 (5.0) 123 (4.8) 
AJCC stage 
 I 4,699 (51.3) 1,867 (48.8) 1,430 (50.6) 1,402 (56.1) 
 II 3,392 (37.1) 1,504 (39.3) 1,063 (37.6) 825 (33.0) 
 III 1,062 (11.6) 453 (11.9) 335 (11.8) 274 (10.9) 
Hormone receptor status 
 ER+, PR+ 5,746 (65.2) 2,361 (64.0) 1,751 (64.6) 1,634 (68.0) 
 ER−, PR+ 276 (3.1) 113 (3.0) 100 (3.7) 63 (2.6) 
 ER+, PR− 1,302 (14.8) 570 (15.4) 380 (14.0) 352 (14.6) 
 ER−, PR− 1,484 (16.9) 648 (17.6) 481 (17.7) 355 (14.8) 
Chemotherapy 
 No 4,402 (47.9) 1,843 (47.9) 1,267 (44.6) 1,292 (51.4) 
 Yes 4,795 (52.1) 2,004 (52.1) 1,572 (55.4) 1,219 (48.6) 
Radiation therapy 
 No 3,595 (38.9) 1,576 (40.8) 1,093 (38.3) 926 (36.7) 
 Yes 5,649 (61.1) 2,290 (59.2) 1,764 (61.7) 1,595 (63.3) 
Hormonal therapy 
 No 2,416 (26.2) 1,036 (26.9) 769 (26.9) 611 (24.3) 
 Yes 6,808 (73.8) 2,815 (73.1) 2,087 (73.1) 1,906 (75.7) 
Surgery type 
 None 18 (0.2) 9 (0.2) 7 (0.2) 2 (0.1) 
 Lumpectomy 4,675 (50.6) 1,842 (47.7) 1,472 (51.5) 1,361 (54.0) 
 Mastectomy 4,553 (49.2) 2,014 (52.1) 1,381 (48.3) 1,158 (45.9) 
Smoking history 
 Never 4,472 (48.2) 2,244 (57.8) 1,375 (48.0) 853 (33.7) 
 Past 4,167 (44.9) 1,388 (35.7) 1,322 (46.1) 1,457 (57.5) 
 Current 646 (6.9) 253 (6.5) 169 (5.9) 224 (8.8) 
Any comorbidity 
 No 5,376 (61.4) 2,005 (54.4) 1,787 (66.0) 1,584 (67.1) 
 Yes 3,373 (38.6) 1,678 (45.6) 920 (34.0) 775 (32.9) 
Met physical activity guidelines 
 No 3,696 (48.9) 1,714 (55.0) 1,104 (45.9) 878 (42.9) 
 Yes 3,869 (51.1) 1,400 (45.0) 1,302 (54.1) 1,167 (57.1) 
Overall n = 9,329Nondrinker (<0.36 g/day) n = 3,907Occasional (0.36 to less than 6 g/day) n = 2,880Regular (≥6 g/day) n = 2,542
Age at diagnosis (mean, SD) 58.8 (10.5) 59.8 (10.8) 57.4 (10.0) 58.7 (10.3) 
Prediagnosis BMI (mean, SD) 26.5 (5.4) 27.6 (6.0) 26.2 (5.1) 25.0 (4.3) 
 n (%) n (%) n (%) n (%) 
Race/ethnicity 
 Non-Hispanic white 8,261 (88.6) 3,302 (84.5) 2,578 (89.5) 2,381 (93.7) 
 Non-Hispanic black 248 (2.7) 149 (3.8) 65 (2.3) 34 (1.4) 
 Asian 238 (2.5) 156 (4.0) 66 (2.3) 16 (0.6) 
 Hispanic 308 (3.3) 153 (3.9) 102 (3.5) 53 (2.1) 
 Other 272 (2.9) 146 (3.8) 69 (2.4) 57 (2.2) 
Education 
 Less than high school 113 (1.2) 65 (1.7) 29 (1.0) 19 (0.7) 
 High school 846 (9.1) 416 (10.7) 242 (8.4) 188 (7.4) 
 Some college 1,652 (17.7) 740 (18.9) 496 (17.2) 416 (16.4) 
 College grad or higher 6,714 (72.0) 2,685 (68.7) 2,113 (73.4) 1,916 (75.5) 
Menopausal status at diagnosis 
 Premenopausal 2,222 (23.8) 843 (21.6) 754 (26.2) 625 (24.6) 
 Postmenopausal 6,613 (70.9) 2,836 (72.6) 1,983 (68.8) 1,794 (70.6) 
 Unknown 494 (5.3) 228 (5.8) 143 (5.0) 123 (4.8) 
AJCC stage 
 I 4,699 (51.3) 1,867 (48.8) 1,430 (50.6) 1,402 (56.1) 
 II 3,392 (37.1) 1,504 (39.3) 1,063 (37.6) 825 (33.0) 
 III 1,062 (11.6) 453 (11.9) 335 (11.8) 274 (10.9) 
Hormone receptor status 
 ER+, PR+ 5,746 (65.2) 2,361 (64.0) 1,751 (64.6) 1,634 (68.0) 
 ER−, PR+ 276 (3.1) 113 (3.0) 100 (3.7) 63 (2.6) 
 ER+, PR− 1,302 (14.8) 570 (15.4) 380 (14.0) 352 (14.6) 
 ER−, PR− 1,484 (16.9) 648 (17.6) 481 (17.7) 355 (14.8) 
Chemotherapy 
 No 4,402 (47.9) 1,843 (47.9) 1,267 (44.6) 1,292 (51.4) 
 Yes 4,795 (52.1) 2,004 (52.1) 1,572 (55.4) 1,219 (48.6) 
Radiation therapy 
 No 3,595 (38.9) 1,576 (40.8) 1,093 (38.3) 926 (36.7) 
 Yes 5,649 (61.1) 2,290 (59.2) 1,764 (61.7) 1,595 (63.3) 
Hormonal therapy 
 No 2,416 (26.2) 1,036 (26.9) 769 (26.9) 611 (24.3) 
 Yes 6,808 (73.8) 2,815 (73.1) 2,087 (73.1) 1,906 (75.7) 
Surgery type 
 None 18 (0.2) 9 (0.2) 7 (0.2) 2 (0.1) 
 Lumpectomy 4,675 (50.6) 1,842 (47.7) 1,472 (51.5) 1,361 (54.0) 
 Mastectomy 4,553 (49.2) 2,014 (52.1) 1,381 (48.3) 1,158 (45.9) 
Smoking history 
 Never 4,472 (48.2) 2,244 (57.8) 1,375 (48.0) 853 (33.7) 
 Past 4,167 (44.9) 1,388 (35.7) 1,322 (46.1) 1,457 (57.5) 
 Current 646 (6.9) 253 (6.5) 169 (5.9) 224 (8.8) 
Any comorbidity 
 No 5,376 (61.4) 2,005 (54.4) 1,787 (66.0) 1,584 (67.1) 
 Yes 3,373 (38.6) 1,678 (45.6) 920 (34.0) 775 (32.9) 
Met physical activity guidelines 
 No 3,696 (48.9) 1,714 (55.0) 1,104 (45.9) 878 (42.9) 
 Yes 3,869 (51.1) 1,400 (45.0) 1,302 (54.1) 1,167 (57.1) 

NOTE: Missing values for covariates were as follows: race/ethnicity (n = 2), education (n = 4), AJCC stage (n = 176), hormone receptor status (n = 521), chemotherapy (n = 132), radiation therapy (n = 85), hormonal therapy (n = 105), surgery type (n = 90), smoking history (n = 44), any comorbidity (n = 580), and met 2008 Physical Activity Guidelines of 10 MET-hours/week or more (n = 1,764; ref. 44).

In the cohort, the mean (SD) g/day of alcohol consumption was 5.79 (11.15), whereas the median (range) was 1.00 (0–149.32; Table 2). Thus, the distribution of alcohol consumption was skewed by a small proportion of heavy drinkers. Among the drinkers (≥0.36 g/day), the mean (SD) consumption was 9.94 (13.14) g/day (median 5.30; range: 0.39–149.32).

Table 2.

Alcohol consumption in the ABCPP

Total alcohol consumption g/day
n (%)Mean (SD)MedianRange
Total cohort 9,329 (100) 5.79 (11.15) 1.00 0.00–149.32 
Nondrinker (<0.36 g/day) 3,907 (41.88) 0.02 (0.05) 0.00 0.00–0.33 
Drinker (≥0.36 g/day) 5,422 (100) 9.94 (13.14) 5.30 0.39–149.32 
 Occasional (0.36 to less than 6 g/day) 2,880 (53.12) 2.23 (1.49) 1.83 0.39–6.00 
 Regular (≥6 g/day) 2,542 (46.88) 18.67 (14.91) 13.80 6.00–149.32 
Total alcohol consumption g/day
n (%)Mean (SD)MedianRange
Total cohort 9,329 (100) 5.79 (11.15) 1.00 0.00–149.32 
Nondrinker (<0.36 g/day) 3,907 (41.88) 0.02 (0.05) 0.00 0.00–0.33 
Drinker (≥0.36 g/day) 5,422 (100) 9.94 (13.14) 5.30 0.39–149.32 
 Occasional (0.36 to less than 6 g/day) 2,880 (53.12) 2.23 (1.49) 1.83 0.39–6.00 
 Regular (≥6 g/day) 2,542 (46.88) 18.67 (14.91) 13.80 6.00–149.32 

NOTE: 0.36 and 6 g/day are approximately 0.25 and 3.5 drinks/week, respectively.

Table 3 gives the associations between postdiagnosis alcohol intake (nondrinker, occasional, regular low, regular medium, and regular high) and breast cancer recurrence and mortality in the overall pooled cohort. Compared with no consumption, regular consumption of alcohol (≥6.0 g/day) was not associated with risk of recurrence at any level (HR for 6 to less than 12 g/day, 1.03; 95% CI, 0.86–1.24; HR for 12 to less than 24 g/day, 1.12; 95% CI, 0.93–1.34; HR for ≥24 g/day, 1.04; 95% CI, 0.84–1.31). Occasional drinking (0.36 to less than 0.6 g/day) was also not associated with recurrence risk (HR, 0.99; 95% CI, 0.87–1.12). No dose–response effect for increasing alcohol consumption was found. When excluding the n = 152 women who had an early recurrence within the first 2 years of their breast cancer diagnosis to examine the potential impact of reverse causality, all the associations remained nonsignificant with no dose–response effect.

Table 3.

Association of alcohol consumption and recurrence and mortality in the ABCPP

Total cohortaExcluding early events (within 2 years of initial breast cancer diagnosis)a
  n = 9,151 (1,487 events) n = 8,987 (1,335 events) 
Recurrence n Events HR (95% CI) Events HR (95% CI) 
Nondrinker (<0.36 g/day) 3,829 624 Ref 549 Ref 
Occasional (0.36 to less than 6 g/day) 2,816 454 0.99 (0.87–1.12) 415 1.02 (0.90–1.17) 
Regular low (6 to less than 12 g/day) 1,002 160 1.03 (0.86–1.24) 146 1.08 (0.89–1.30) 
Regular medium (12 to less than 24 g/day) 928 156 1.12 (0.93–1.34) 139 1.12 (0.93–1.36) 
Regular high (≥24 g/day) 576 93 1.04 (0.84–1.31) 86 1.09 (0.86–1.37) 
P for trend   0.32  0.21 
  n = 9,325 (1,542 events) n = 9,286 (1,510 events) 
Total mortality n Events HR (95% CI) Events HR (95% CI) 
Nondrinker (<0.36 g/day) 3,906 712 Ref 697 Ref 
Occasional (0.36 to less than 6 g/day) 2,880 438 0.91 (0.81–1.03) 429 0.91 (0.81–1.04) 
Regular low (6 to less than 12 g/day) 1,013 166 1.01 (0.84–1.20) 162 1.00 (0.84–1.20) 
Regular medium (12 to less than 24 g/day) 945 140 0.89 (0.74–1.07) 137 0.89 (0.74–1.07) 
Regular high (≥24 g/day) 581 86 0.79 (0.63–1.00) 85 0.80 (0.64–1.01) 
P for trend   0.06  0.07 
  n = 9,306 (911 events) n = 9,267 (885 events) 
Breast cancer mortality n Events HR (95% CI) Events HR (95% CI) 
Nondrinker (<0.36 g/day) 3,900 402 Ref 390 Ref 
Occasional (0.36 to less than 6 g/day) 2,875 276 0.94 (0.80–1.10) 268 0.94 (0.80–1.10) 
Regular low (6 to less than 12 g/day) 1,009 102 1.06 (0.85–1.33) 98 1.05 (0.84–1.32) 
Regular medium (12 to less than 24 g/day) 942 85 0.93 (0.73–1.18) 83 0.93 (0.73–1.19) 
Regular high (≥24 g/day) 580 46 0.80 (0.59–1.09) 46 0.83 (0.60–1.13) 
P for trend   0.29  0.36 
  n = 9,306 (156 events) n = 9,267 (155 events) 
CVD Mortality n Events HR (95% CI) Events HR (95% CI) 
Nondrinker (<0.36 g/day) 3,900 88 Ref 87 Ref 
Occasional (0.36 to less than 6 g/day) 2,875 37 0.83 (0.56–1.23) 37 0.84 (0.57–1.24) 
Regular low (6 to less than 12 g/day) 1,009 14 0.88 (0.49–1.58) 14 0.89 (0.50–1.60) 
Regular medium (12 to less than 24 g/day) 942 11 0.72 (0.38–1.37) 11 0.73 (0.38–1.39) 
Regular high (≥24 g/day) 580 0.48 (0.21–1.12) 0.48 (0.21–1.13) 
P for trend   0.07  0.07 
Total cohortaExcluding early events (within 2 years of initial breast cancer diagnosis)a
  n = 9,151 (1,487 events) n = 8,987 (1,335 events) 
Recurrence n Events HR (95% CI) Events HR (95% CI) 
Nondrinker (<0.36 g/day) 3,829 624 Ref 549 Ref 
Occasional (0.36 to less than 6 g/day) 2,816 454 0.99 (0.87–1.12) 415 1.02 (0.90–1.17) 
Regular low (6 to less than 12 g/day) 1,002 160 1.03 (0.86–1.24) 146 1.08 (0.89–1.30) 
Regular medium (12 to less than 24 g/day) 928 156 1.12 (0.93–1.34) 139 1.12 (0.93–1.36) 
Regular high (≥24 g/day) 576 93 1.04 (0.84–1.31) 86 1.09 (0.86–1.37) 
P for trend   0.32  0.21 
  n = 9,325 (1,542 events) n = 9,286 (1,510 events) 
Total mortality n Events HR (95% CI) Events HR (95% CI) 
Nondrinker (<0.36 g/day) 3,906 712 Ref 697 Ref 
Occasional (0.36 to less than 6 g/day) 2,880 438 0.91 (0.81–1.03) 429 0.91 (0.81–1.04) 
Regular low (6 to less than 12 g/day) 1,013 166 1.01 (0.84–1.20) 162 1.00 (0.84–1.20) 
Regular medium (12 to less than 24 g/day) 945 140 0.89 (0.74–1.07) 137 0.89 (0.74–1.07) 
Regular high (≥24 g/day) 581 86 0.79 (0.63–1.00) 85 0.80 (0.64–1.01) 
P for trend   0.06  0.07 
  n = 9,306 (911 events) n = 9,267 (885 events) 
Breast cancer mortality n Events HR (95% CI) Events HR (95% CI) 
Nondrinker (<0.36 g/day) 3,900 402 Ref 390 Ref 
Occasional (0.36 to less than 6 g/day) 2,875 276 0.94 (0.80–1.10) 268 0.94 (0.80–1.10) 
Regular low (6 to less than 12 g/day) 1,009 102 1.06 (0.85–1.33) 98 1.05 (0.84–1.32) 
Regular medium (12 to less than 24 g/day) 942 85 0.93 (0.73–1.18) 83 0.93 (0.73–1.19) 
Regular high (≥24 g/day) 580 46 0.80 (0.59–1.09) 46 0.83 (0.60–1.13) 
P for trend   0.29  0.36 
  n = 9,306 (156 events) n = 9,267 (155 events) 
CVD Mortality n Events HR (95% CI) Events HR (95% CI) 
Nondrinker (<0.36 g/day) 3,900 88 Ref 87 Ref 
Occasional (0.36 to less than 6 g/day) 2,875 37 0.83 (0.56–1.23) 37 0.84 (0.57–1.24) 
Regular low (6 to less than 12 g/day) 1,009 14 0.88 (0.49–1.58) 14 0.89 (0.50–1.60) 
Regular medium (12 to less than 24 g/day) 942 11 0.72 (0.38–1.37) 11 0.73 (0.38–1.39) 
Regular high (≥24 g/day) 580 0.48 (0.21–1.12) 0.48 (0.21–1.13) 
P for trend   0.07  0.07 

NOTE: 0.36, 6, and 12 g/day are approximately 0.25, 3.5, and 7 drinks/week, respectively.

aAdjusted for age at diagnosis, AJCC stage, race/ethnicity, education, menopausal status around diagnosis, hormone receptor status, surgery, treatment (radiation therapy, chemotherapy, and hormonal therapy), smoking, physical activity, prediagnosis BMI, and comorbidity.

Examining risk of overall mortality, breast cancer mortality, and CVD mortality, no significant associations were found for any amount of alcohol intake. However, a borderline statistically significant trend of increasing consumption with decreasing risk of CVD death was observed for regular consumption of 24 g/day or more (HR, 0.48; 95% CI, 0.21–1.12; P for trend = 0.07). A corresponding decreased risk of overall death was also found for regular consumption of 24 g/day or more (HR, 0.79; 95% CI, 0.63–1.00; P for trend = 0.06).

Table 4 gives stratified analyses of postdiagnosis alcohol consumption (nondrinker, occasional, and regular) and recurrence by menopausal status at diagnosis, ER status, and prediagnosis obesity. Significant effect modification was present for risk of recurrence by menopausal status (P for interaction = 0.027) and ER status (P for interaction = 0.012). Among postmenopausal women at diagnosis, increasing consumption of alcohol postdiagnosis was associated with an increased risk of recurrence (P for trend = 0.04), and the increased risk associated with regular consumption (≥6.0 g/day) was statistically significant (HR, 1.19; 95% CI, 1.01–1.40). In contrast, among premenopausal women at diagnosis, occasional drinking (0.36 to less than 0.6 g/day) postdiagnosis was associated with a decreased risk of recurrence (HR, 0.75; 95% CI, 0.59–0.94) with no apparent dose–response effect. While no associations were observed among ER+ women, occasional alcohol consumption (0.36 to less than 6.0 g/day) in ER− women was associated with decreased risk of recurrence (HR, 0.70; 95% CI, 0.53–0.92), whereas regular consumption (≥6.0 g/day) had no association with recurrence (HR, 1.03; 95% CI, 0.78–1.36). Associations were similar across the obese and nonobese groups with no evidence of effect modification (Table 4).

Table 4.

Association of alcohol consumption and recurrence in the ABCPP, stratified by estrogen-related factors

PremenopausalaPostmenopausala
n = 2,209 (447 events)n = 6,456 (938 events)
Menopausal statusnEventsHR (95% CI)nEventsHR (95% CI)
Nondrinker (<0.36 g/day)a 838 188 Ref 2,765 389 Ref 
Occasional (0.36 to less 6 g/day) 749 133 0.75 (0.59–0.94) 1,928 287 1.10 (0.94–1.29) 
Regular (≥6 g/day) 622 126 0.91 (0.72–1.16) 1,763 262 1.19 (1.01–1.40) 
P for trend   0.30   0.04 
P for interaction = 0.027       
 ER negativea ER positivea 
ER receptor status n = 1,738 (328 events) n = 7,027 (1,098 events) 
 n Events HR (95% CI) n Events HR (95% CI) 
Non-drinker (<0.36 g/day) 750 156 Ref 2,924 444 Ref 
Occasional (0.36 to less than6 g/day) 575 87 0.70 (0.53–0.92) 2,116 348 1.09 (0.94–1.26) 
Regular (≥6 g/day) 413 85 1.03 (0.78–1.36) 1,987 306 1.08 (0.92–1.26) 
P for trend   0.76   0.31 
P for interaction = 0.012       
 Obese (BMI ≥ 30 kg/m2)a Nonobese (BMI < 30 kg/m2)a 
Prediagnosis BMI n = 1,909 (318 events) n = 7,107 (1,143 events) 
 n Events HR (95% CI) n Events HR (95% CI) 
Nondrinker (<0.36 g/day) 1,075 180 Ref 2,691 429 Ref 
Occasional (0.36 to less than 6 g/day) 543 86 1.01 (0.77–1.32) 2,243 362 0.99 (0.85–1.14) 
Regular (≥6 g/day) 291 52 1.15 (0.83–1.60) 2,173 352 1.07 (0.92–1.23) 
P for trend   0.47   0.43 
P for interaction = 0.94       
PremenopausalaPostmenopausala
n = 2,209 (447 events)n = 6,456 (938 events)
Menopausal statusnEventsHR (95% CI)nEventsHR (95% CI)
Nondrinker (<0.36 g/day)a 838 188 Ref 2,765 389 Ref 
Occasional (0.36 to less 6 g/day) 749 133 0.75 (0.59–0.94) 1,928 287 1.10 (0.94–1.29) 
Regular (≥6 g/day) 622 126 0.91 (0.72–1.16) 1,763 262 1.19 (1.01–1.40) 
P for trend   0.30   0.04 
P for interaction = 0.027       
 ER negativea ER positivea 
ER receptor status n = 1,738 (328 events) n = 7,027 (1,098 events) 
 n Events HR (95% CI) n Events HR (95% CI) 
Non-drinker (<0.36 g/day) 750 156 Ref 2,924 444 Ref 
Occasional (0.36 to less than6 g/day) 575 87 0.70 (0.53–0.92) 2,116 348 1.09 (0.94–1.26) 
Regular (≥6 g/day) 413 85 1.03 (0.78–1.36) 1,987 306 1.08 (0.92–1.26) 
P for trend   0.76   0.31 
P for interaction = 0.012       
 Obese (BMI ≥ 30 kg/m2)a Nonobese (BMI < 30 kg/m2)a 
Prediagnosis BMI n = 1,909 (318 events) n = 7,107 (1,143 events) 
 n Events HR (95% CI) n Events HR (95% CI) 
Nondrinker (<0.36 g/day) 1,075 180 Ref 2,691 429 Ref 
Occasional (0.36 to less than 6 g/day) 543 86 1.01 (0.77–1.32) 2,243 362 0.99 (0.85–1.14) 
Regular (≥6 g/day) 291 52 1.15 (0.83–1.60) 2,173 352 1.07 (0.92–1.23) 
P for trend   0.47   0.43 
P for interaction = 0.94       

NOTE: 0.36 and 6 g/day are approximately 0.25 and 3.5 drinks/week, respectively.

aAdjusted for age at diagnosis, AJCC stage, race/ethnicity, education, surgery, treatment (radiation therapy, chemotherapy, and hormonal therapy), smoking, physical activity, prediagnosis BMI, and comorbidity while excluding menopausal status and hormone receptor status as appropriate depending on stratified model.

Stratified analyses of alcohol intake and mortality outcomes (total and breast cancer specific) by menopausal status, hormone receptor status, and obesity were not significant (data not shown).

In this large pooled analysis of 9,329 US breast cancer survivors, alcohol consumption after a breast cancer diagnosis was not associated with increased risk of recurrence or total mortality in general, yet some varying risk associations were observed by estrogenic factors. Specifically, compared with no drinking, regular consumption of more than 3 drinks per week (approximately half a drink or more per day) was associated with an approximate 20% increased relative risk of recurrence among postmenopausal women. While not statistically significant yet consistent with previous studies, there was a suggestive inverse trend of alcohol intake with decreased cardiovascular-related mortality despite the limited number of CVD deaths in the cohort. These results suggest that alcohol intake is generally not associated with poor outcomes after a breast cancer diagnosis in the largest analytic sample size to date. However, alcohol might be associated with a modestly increased risk of recurrence in postmenopausal women, but this finding requires independent corroboration in other large studies.

A possible explanation as to why postdiagnosis alcohol intake was not associated with risk of breast cancer recurrence among all women yet associated with increased risk among postmenopausal women only is that the estrogenic effects of alcohol on circulating estrogens might vary depending on the endogenous estrogen environment (29, 33). Among postmenopausal women with breast cancer, sex hormone concentrations have been shown to be stable over time (52, 53), yet those in premenopausal women with breast cancer can fluctuate greatly because of treatment effects and age (53–55). Furthermore, women who experience menopause resulting from treatment likely have higher estrogen levels than women who are already postmenopausal at diagnosis. Overall, more research is needed to elucidate the potentially differing biologic mechanisms of alcohol intake among premenopausal and postmenopausal women with breast cancer.

We report an increased risk of recurrence among women who were postmenopausal at breast cancer diagnosis and a corresponding decreased risk of recurrence among those who were premenopausal at diagnosis. Previous large studies on alcohol and incident breast cancer have reported an elevated risk among postmenopausal women (56–58), and when we excluded the second primary breast cancers (n = 135) from our menopausal analysis, the recurrence findings were essentially unchanged. Furthermore, a linear increase in estrone sulfate levels (the most abundant, long-lasting estrogen in postmenopausal women) was previously observed across alcohol intakes of 0 to 30 g/day or more in the NHS (59).

While our results suggest a possible interaction of postdiagnosis alcohol intake by ER tumor status, because of the limited sample size of women with ER− tumors who had an event of interest, we cannot rule out chance and residual confounding. Nonetheless, alcohol has been found to increase the expression and proliferation of ERs in cultured human breast cancer cells (32, 60) and has been found to be associated with the development of incident ER+ breast cancer in postmenopausal women (61, 62). When we conducted a subgroup analysis among the 5,082 postmenopausal, ER+ women in our cohort, any level of alcohol intake was associated with a borderline significant, increased risk of recurrence (HR, 1.21; 95% CI, 0.99–1.45 for <6.0 g/day and HR, 1.19; 95% CI, CI: 0.99–1.45 for ≥6.0 g/day).

The 3 studies included in this pooled analysis have previously published individual analyses on alcohol and breast cancer prognosis, yet they either did not examine recurrence specifically (NHS) or were limited by sample size to adequately examine potential interactions by estrogen-related factors (all studies). This pooled analysis includes new analyses of recurrence, longer follow-up, and an expanded number of NHS women.

In the earlier WHEL study of 3,088 early-stage breast cancer survivors followed for 7.3 years, moderate (≥1 drink/day) alcohol intake postdiagnosis was associated with reduced overall mortality, particularly among nonobese women (13), yet was not associated with recurrence. In the NHS, moderate alcohol intake postdiagnosis was not associated with total mortality among 1,982 women diagnosed with invasive breast cancer and followed for 13.1 years (19). Similarly, in the LACE study of 1,897 women diagnosed with early-stage breast cancer and followed for 7.4 years, regular consumption of alcohol (≥0.5 drink/day) after diagnosis was not associated with overall death (25). In agreement with this pooled analysis, an elevated risk of recurrence with alcohol intake was observed among postmenopausal women in LACE, whereas WHEL and NHS did not examine alcohol associations by menopausal status.

Strengths of this pooled study include being the largest to date of breast cancer survivors with data on postdiagnosis alcohol consumption, and having the ability to adjust for important prognostic and treatment-related factors, including BMI, smoking, menopausal status, cancer stage, hormone receptor status, and treatment. Our study population had a wide range of alcohol intake, allowing adequate exploration of higher levels of drinking and outcomes. The mean level in the pooled cohort among drinkers was 9.9 g/day (median 5.3), which is in agreement with mean levels reported in studies of healthy female drinkers (3.2–12.6 g/day; ref. 5). Pooling data also improved the statistical power to conduct stratified analyses by estrogen-related factors.

Of note, our analysis did not examine patterns of change in postdiagnosis alcohol consumption, as follow-up assessments across cohorts were not temporally uniform relative to baseline. However, most women (98%) remained in the same or adjacent category of intake at their subsequent follow-ups. Furthermore, change in alcohol consumption from prediagnosis to postdiagnosis may also be a contributing factor in associations of alcohol and mortality. Specifically, women who more regularly consumed alcohol before their breast cancer diagnosis and then substantially reduced or stopped their intake after diagnosis may have lower overall mortality compared with lifelong nondrinkers or low drinkers. While we do not have information on prediagnosis alcohol intake on the entire pooled cohort, perhaps this hypothesis explains, in part, the attenuated CVD mortality association observed in our analyses. We also relied on self-reported alcohol use, yet in NHS and WHEL, levels have been shown to be highly reproducible using food records and 24-hour recalls, respectively (13, 63).

In summary, we observed that alcohol consumption after a breast cancer diagnosis was generally not associated with risk of recurrence, or total or breast cancer-related mortality. A suggestive trend of alcohol intake and decreased risk of cardiovascular-related deaths was noted. However, regular drinking of more than 3 drinks per week (half a drink or more per day) was associated with higher risk of recurrence in postmenopausal women. Given that consuming alcohol is a potentially modifiable lifestyle factor following a breast cancer diagnosis, further confirmation is warranted in other large prospective studies of breast cancer survivors with long-term follow-up and detailed information on alcohol intake and estrogen-related covariates.

No potential conflicts of interest were disclosed.

Conception and design: M.L. Kwan, W.Y. Chen, X.-O. Shu, J.P. Pierce, B.J. Caan

Development of methodology: M.L. Kwan, W.Y. Chen, J.P. Pierce, B.J. Caan

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): W.Y. Chen, S. Nechuta, M. Holmes, J.P. Pierce, B.J. Caan

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M.L. Kwan, W.Y. Chen, S.W. Flatt, E.K. Weltzien, S. Nechuta, R.E. Patterson, X.-O. Shu, B.J. Caan

Writing, review, and/or revision of the manuscript: M.L. Kwan, W.Y. Chen, S.W. Flatt, E.K. Weltzien, S. Nechuta, E.M. Poole, M. Holmes, R.E. Patterson, X.-O. Shu, J.P. Pierce, B.J. Caan

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.L. Kwan, S.W. Flatt, E.K. Weltzien, S. Nechuta, E.M. Poole

Study supervision: B.J. Caan

This work was supported by the National Cancer Institute (3R01CA118229-03S1). Funding for each individual cohort participating in the After Breast Cancer Pooling Project is as follows: The SBCSS was supported by the Department of Defense (DAMD 17-02-1-0607); and the National Cancer Institute (R01 CA118229). The WHEL Study was supported by the Susan G. Komen Foundation (#KG100988). The LACE Study was supported by the National Cancer Institute (R01 CA129059). The NHS was supported by the National Cancer Institute (P01 CA87969, T32 CA009001).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations)
,
National Cancer Institute
.
Bethesda, MD
; 
2012
.
2.
American Cancer Society
. 
Breast Cancer Facts & Figures 2011–2012
.
Atlanta
:
American Cancer Society, Inc
.
3.
Kushi
LH
,
Doyle
C
,
McCullough
M
,
Rock
CL
,
Demark-Wahnefried
W
,
Bandera
EV
, et al
American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity
.
CA Cancer J Clin
2012
;
62
:
30
67
.
4.
World Cancer Research Fund/American Institute for Cancer Research
. 
Food, nutrition, physical activity, and the prevention of cancer: a global perspective
.
Washington, D.C.
:
AICR
; 
2007
.
5.
Smith-Warner
SA
,
Spiegelman
D
,
Yaun
SS
,
van den Brandt
PA
,
Folsom
AR
,
Goldbohm
RA
, et al
Alcohol and breast cancer in women: a pooled analysis of cohort studies
.
Jama
1998
;
279
:
535
40
.
6.
Hebert
JR
,
Hurley
TG
,
Ma
Y
. 
The effect of dietary exposures on recurrence and mortality in early stage breast cancer
.
Breast Cancer Res Treat
1998
;
51
:
17
28
.
7.
Jain
MG
,
Ferrenc
RG
,
Rehm
JT
,
Bondy
SJ
,
Rohan
TE
,
Ashley
MJ
, et al
Alcohol and breast cancer mortality in a cohort study
.
Breast Cancer Res Treat
2000
;
64
:
201
9
.
8.
McDonald
PA
,
Williams
R
,
Dawkins
F
,
Adams-Campbell
LL
. 
Breast cancer survival in African American women: is alcohol consumption a prognostic indicator?
Cancer Causes Control
2002
;
13
:
543
9
.
9.
Allemani
C
,
Berrino
F
,
Krogh
V
,
Sieri
S
,
Pupa
SM
,
Tagliabue
E
, et al
Do pre-diagnostic drinking habits influence breast cancer survival?
Tumori
2011
;
97
:
142
8
.
10.
Barnett
GC
,
Shah
M
,
Redman
K
,
Easton
DF
,
Ponder
BA
,
Pharoah
PD
. 
Risk factors for the incidence of breast cancer: do they affect survival from the disease?
J Clin Oncol
2008
;
26
:
3310
6
.
11.
Pierce
JP
,
Stefanick
ML
,
Flatt
SW
,
Natarajan
L
,
Sternfeld
B
,
Madlensky
L
, et al
Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity
.
J Clin Oncol
2007
;
25
:
2345
51
.
12.
Reding
KW
,
Daling
JR
,
Doody
DR
,
O'Brien
CA
,
Porter
PL
,
Malone
KE
. 
Effect of prediagnostic alcohol consumption on survival after breast cancer in young women
.
Cancer Epidemiol Biomarkers Prev
2008
;
17
:
1988
96
.
13.
Flatt
SW
,
Thomson
CA
,
Gold
EB
,
Natarajan
L
,
Rock
CL
,
Al-Delaimy
WK
, et al
Low to moderate alcohol intake is not associated with increased mortality after breast cancer
.
Cancer Epidemiol Biomarkers Prev
2010
;
19
:
681
8
.
14.
Harris
HR
,
Bergkvist
L
,
Wolk
A
. 
Alcohol intake and mortality among women with invasive breast cancer
.
Br J Cancer
2012
;
106
:
592
5
.
15.
Dal Maso
L
,
Zucchetto
A
,
Talamini
R
,
Serraino
D
,
Stocco
CF
,
Vercelli
M
, et al
Effect of obesity and other lifestyle factors on mortality in women with breast cancer
.
Int J Cancer
2008
;
123
:
2188
94
.
16.
Ewertz
M
,
Gillanders
S
,
Meyer
L
,
Zedeler
K
. 
Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer
.
Int J Cancer
1991
;
49
:
526
30
.
17.
Franceschi
S
,
Dal Maso
L
,
Zucchetto
A
,
Talamini
R
. 
Alcohol consumption and survival after breast cancer
.
Cancer Epidemiol Biomarkers Prev
2009
;
18
:
1011
2
;
author reply 2–3
.
18.
Holm
LE
,
Nordevang
E
,
Hjalmar
ML
,
Lidbrink
E
,
Callmer
E
,
Nilsson
B
. 
Treatment failure and dietary habits in women with breast cancer
.
J Natl Cancer Inst
1993
;
85
:
32
6
.
19.
Holmes
MD
,
Stampfer
MJ
,
Colditz
GA
,
Rosner
B
,
Hunter
DJ
,
Willett
WC
. 
Dietary factors and the survival of women with breast carcinoma
.
Cancer
1999
;
86
:
826
35
.
20.
Rohan
TE
,
Hiller
JE
,
McMichael
AJ
. 
Dietary factors and survival from breast cancer
.
Nutr Cancer
1993
;
20
:
167
77
.
21.
Zhang
S
,
Folsom
AR
,
Sellers
TA
,
Kushi
LH
,
Potter
JD
. 
Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. The Iowa Women's Health Study
.
Cancer
1995
;
76
:
275
83
.
22.
Goodwin
PJ
,
Ennis
M
,
Pritchard
KI
,
Koo
J
,
Trudeau
ME
,
Hood
N
. 
Diet and breast cancer: evidence that extremes in diet are associated with poor survival
.
J Clin Oncol
2003
;
21
:
2500
7
.
23.
Beasley
JM
,
Newcomb
PA
,
Trentham-Dietz
A
,
Hampton
JM
,
Bersch
AJ
,
Passarelli
MN
, et al
Post-diagnosis dietary factors and survival after invasive breast cancer
.
Breast Cancer Res Treat
2011
;
128
:
229
36
.
24.
Hellmann
SS
,
Thygesen
LC
,
Tolstrup
JS
,
Gronbaek
M
. 
Modifiable risk factors and survival in women diagnosed with primary breast cancer: results from a prospective cohort study
.
Eur J Cancer Prev
2010
;
19
:
366
73
.
25.
Kwan
ML
,
Kushi
LH
,
Weltzien
E
,
Tam
EK
,
Castillo
A
,
Sweeney
C
, et al
Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the life after cancer epidemiology study
.
J Clin Oncol
2010
;
28
:
4410
6
.
26.
Saxe
GA
,
Rock
CL
,
Wicha
MS
,
Schottenfeld
D
. 
Diet and risk for breast cancer recurrence and survival
.
Breast Cancer Res Treat
1999
;
53
:
241
53
.
27.
Bandera
EV
,
August
DA
. 
Alcohol consumption and breast cancer survival
.
J Clin Oncol
2009
;
27
:
1727
;
author reply 8
.
28.
Holmes
MD
. 
Challenge of balancing alcohol intake
.
J Clin Oncol
2010
;
28
:
4403
4
.
29.
Dorgan
JF
,
Baer
DJ
,
Albert
PS
,
Judd
JT
,
Brown
ED
,
Corle
DK
, et al
Serum hormones and the alcohol-breast cancer association in postmenopausal women
.
J Natl Cancer Inst
2001
;
93
:
710
5
.
30.
Dumitrescu
RG
,
Shields
PG
. 
The etiology of alcohol-induced breast cancer
.
Alcohol
2005
;
35
:
213
25
.
31.
Seitz
HK
,
Maurer
B
. 
The relationship between alcohol metabolism, estrogen levels, and breast cancer risk
.
Alcohol Res Health
2007
;
30
:
42
3
.
32.
Singletary
KW
,
Gapstur
SM
. 
Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms
.
Jama
2001
;
286
:
2143
51
.
33.
Reichman
ME
,
Judd
JT
,
Longcope
C
,
Schatzkin
A
,
Clevidence
BA
,
Nair
PP
, et al
Effects of alcohol consumption on plasma and urinary hormone concentrations in premenopausal women
.
J Natl Cancer Inst
1993
;
85
:
722
7
.
34.
Nechuta
SJ
,
Caan
BJ
,
Chen
WY
,
Flatt
SW
,
Lu
W
,
Patterson
RE
, et al
The After Breast Cancer Pooling Project: rationale, methodology, and breast cancer survivor characteristics
.
Cancer Causes Control
2011
;
22
:
1319
31
.
35.
Shu
XO
,
Zheng
Y
,
Cai
H
,
Gu
K
,
Chen
Z
,
Zheng
W
, et al
Soy food intake and breast cancer survival
.
Jama
2009
;
302
:
2437
43
.
36.
Caan
B
,
Sternfeld
B
,
Gunderson
E
,
Coates
A
,
Quesenberry
C
,
Slattery
ML
. 
Life After Cancer Epidemiology (LACE) Study: a cohort of early stage breast cancer survivors (United States)
.
Cancer Causes Control
2005
;
16
:
545
56
.
37.
Pierce
JP
,
Faerber
S
,
Wright
FA
,
Rock
CL
,
Newman
V
,
Flatt
SW
, et al
A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study
.
Control Clin Trials
2002
;
23
:
728
56
.
38.
Colditz
GA
,
Hankinson
SE
. 
The Nurses' Health Study: lifestyle and health among women
.
Nat Rev Cancer
2005
;
5
:
388
96
.
39.
Block
G
,
Hartman
AM
,
Dresser
CM
,
Carroll
MD
,
Gannon
J
,
Gardner
L
. 
A data-based approach to diet questionnaire design and testing
.
Am J Epidemiol
1986
;
124
:
453
69
.
40.
Ritenbaugh
C
,
Aickin
M
,
Taren
D
,
Teufel
N
,
Graver
E
,
Woolf
K
, et al
Use of a food frequency questionnaire to screen for dietary eligibility in a randomized cancer prevention phase III trial
.
Cancer Epidemiol Biomarkers Prev
1997
;
6
:
347
54
.
41.
Patterson
RE
,
Kristal
AR
,
Tinker
LF
,
Carter
RA
,
Bolton
MP
,
Agurs-Collins
T
. 
Measurement characteristics of the Women's Health Initiative food frequency questionnaire
.
Ann Epidemiol
1999
;
9
:
178
87
.
42.
Centers for Disease Control and Prevention
. http://www.cdc.gov/alcohol/fact-sheets/alcohol-use.htm
[Accessed July 15, 2012]
.
43.
Rock
CL
,
Doyle
C
,
Demark-Wahnefried
W
,
Meyerhardt
J
,
Courneya
KS
,
Schwartz
AL
, et al
Nutrition and physical activity guidelines for cancer survivors
.
CA Cancer J Clin
2012
;
62
:
243
74
.
44.
2008 Physical Activity Guidelines for Americans
. http://www.health.gov/paguidelines/
[Accessed June 28, 2012]
.
45.
Kwan
ML
,
Chen
WY
,
Kroenke
CH
,
Weltzien
EK
,
Beasley
JM
,
Nechuta
SJ
, et al
Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project
.
Breast Cancer Res Treat
2011
;
132
:
729
39
.
46.
Ernst
MF
,
van de Poll-Franse
LV
,
Roukema
JA
,
Coebergh
JW
,
van Gestel
CM
,
Vreugdenhil
G
, et al
Trends in the prognosis of patients with primary metastatic breast cancer diagnosed between 1975 and 2002
.
Breast
2007
;
16
:
344
51
.
47.
Hosmer
DW
,
Lemeshow
S
. 
Applied survival analysis: regression modeling of time to event data
.
New York
:
John Wiley & Sons, Inc.
; 
1999
.
48.
Smith-Warner
SA
,
Spiegelman
D
,
Ritz
J
,
Albanes
D
,
Beeson
WL
,
Bernstein
L
, et al
Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer
.
Am J Epidemiol
2006
;
163
:
1053
64
.
49.
DerSimonian
R
,
Laird
N
. 
Meta-analysis in clinical trials
.
Control Clin Trials
1986
;
7
:
177
88
.
50.
Therneau
TM
,
Grambsch
PM
. 
Modeling survival data: extending the Cox model
.
New York
:
Springer-Verlag
; 
2000
.
51.
Mickey
RM
,
Greenland
S
. 
The impact of confounder selection criteria on effect estimation
.
Am J Epidemiol
1989
;
129
:
125
37
.
52.
Emond
JA
,
Patterson
RE
,
Natarajan
L
,
Laughlin
GA
,
Gold
EB
,
Pierce
JP
. 
Sex hormone concentrations and the risk of breast cancer recurrence in postmenopausal women without hot flashes
.
Cancer Epidemiol Biomarkers Prev
2011
;
20
:
939
45
.
53.
Jordan
VC
,
Fritz
NF
,
Tormey
DC
. 
Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer
.
Cancer Res
1987
;
47
:
624
30
.
54.
Jordan
VC
,
Fritz
NF
,
Langan-Fahey
S
,
Thompson
M
,
Tormey
DC
. 
Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent
.
J Natl Cancer Inst
1991
;
83
:
1488
91
.
55.
Ravdin
PM
,
Fritz
NF
,
Tormey
DC
,
Jordan
VC
. 
Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen
.
Cancer Res
1988
;
48
:
1026
9
.
56.
Chen
WY
,
Rosner
B
,
Hankinson
SE
,
Colditz
GA
,
Willett
WC
. 
Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk
.
Jama
2011
;
306
:
1884
90
.
57.
Hiatt
RA
,
Klatsky
AL
,
Armstrong
MA
. 
Alcohol consumption and the risk of breast cancer in a prepaid health plan
.
Cancer Res
1988
;
48
:
2284
7
.
58.
Willett
WC
,
Stampfer
MJ
,
Colditz
GA
,
Rosner
BA
,
Hennekens
CH
,
Speizer
FE
. 
Moderate alcohol consumption and the risk of breast cancer
.
N Engl J Med
1987
;
316
:
1174
80
.
59.
Hankinson
SE
,
Willett
WC
,
Manson
JE
,
Hunter
DJ
,
Colditz
GA
,
Stampfer
MJ
, et al
Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women
.
J Natl Cancer Inst
1995
;
87
:
1297
302
.
60.
Fan
S
,
Meng
Q
,
Gao
B
,
Grossman
J
,
Yadegari
M
,
Goldberg
ID
, et al
Alcohol stimulates estrogen receptor signaling in human breast cancer cell lines
.
Cancer Res
2000
;
60
:
5635
9
.
61.
Deandrea
S
,
Talamini
R
,
Foschi
R
,
Montella
M
,
Dal Maso
L
,
Falcini
F
, et al
Alcohol and breast cancer risk defined by estrogen and progesterone receptor status: a case-control study
.
Cancer Epidemiol Biomarkers Prev
2008
;
17
:
2025
8
.
62.
Suzuki
R
,
Ye
W
,
Rylander-Rudqvist
T
,
Saji
S
,
Colditz
GA
,
Wolk
A
. 
Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study
.
J Natl Cancer Inst
2005
;
97
:
1601
8
.
63.
Giovannucci
E
,
Colditz
G
,
Stampfer
MJ
,
Rimm
EB
,
Litin
L
,
Sampson
L
, et al
The assessment of alcohol consumption by a simple self-administered questionnaire
.
Am J Epidemiol
1991
;
133
:
810
7
.